🇺🇸 FDA
Patent

US 8841302

HCV inhibitor and therapeutic agent combinations

granted A61KA61K31/00A61K31/404

Quick answer

US patent 8841302 (HCV inhibitor and therapeutic agent combinations) held by PTC THERAPEUTICS, INC. expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PTC THERAPEUTICS, INC.
Grant date
Tue Sep 23 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/00, A61K31/404, A61K45/06, A61P